Aripiprazole side effects: akathisia, insomnia, and impulse-control issues

Aripiprazole (Abilify) has a side effect profile unlike any other antipsychotic. It is generally easier on weight and sedation than olanzapine or quetiapine, but the trade-off is a higher rate of restlessness, sleep disruption, and — in a small but important minority — compulsive behaviours that can be life-altering. This guide walks through what to expect and what tends to help.

Akathisia: the most common reason people stop

What it feels like: A subjective inner restlessness, often combined with an inability to sit or stand still. Patients describe pacing, rocking, crossing and uncrossing their legs, and an almost unbearable urge to keep moving. Some describe it as "feeling like my skin is screaming." It is the single most common reason patients discontinue aripiprazole.

When it appears: Most often in the first 1–4 weeks, and after dose increases.

What helps:

• Telling your prescriber early — many people don't realise akathisia is a known side effect and quietly suffer
• Lowering the dose, when clinically possible
• Adding a beta-blocker (often propranolol) is a common evidence-based strategy
• Benzodiazepines are sometimes used short-term, weighed against dependency risk
• Switching antipsychotics if the akathisia doesn't respond

For more on the spectrum of movement-related side effects, see our guide to extrapyramidal symptoms.

Insomnia and activation

What it feels like: Difficulty falling asleep, lighter sleep, or feeling "wired" through the day. Unlike many antipsychotics that sedate, aripiprazole can do the opposite.

What helps:

• Moving the dose to morning rather than evening
• Sleep hygiene basics — consistent schedule, dim light at night, no screens in bed
• Sometimes a short-term sleep aid is considered
• Caffeine timing matters more than usual

Nausea, headache, and gastrointestinal effects

Common in the first weeks. Taking aripiprazole with food often helps. Constipation can also occur and is usually managed with hydration, fibre, and movement.

Impulse-control problems: a small but serious risk

In 2016 the FDA issued a Drug Safety Communication formally adding warnings about pathological gambling and other impulse-control disorders to aripiprazole's label, later extended to brexpiprazole and cariprazine. The mechanism is thought to be related to D3 receptor activity in reward pathways. The behaviours typically resolve when the medication is reduced or stopped, but the financial and personal damage can be severe before anyone connects the dots. This is one reason families and partners are sometimes asked to watch for changes in behaviour.

Weight and metabolic effects

Aripiprazole is one of the lighter antipsychotics on weight gain, but it is not weight-neutral. Average weight gain in the first year is modest — often a few pounds — but a meaningful minority of patients gain significantly more. Baseline weight, lipid panel, and fasting glucose should still be checked, and again periodically. See our guide on managing antipsychotic-related weight gain for practical strategies.

Tardive dyskinesia

All dopamine-acting antipsychotics carry some long-term risk of tardive dyskinesia (involuntary movements, often of the face and tongue). Aripiprazole's risk appears lower than first-generation antipsychotics but is not zero. Periodic screening with the AIMS (Abnormal Involuntary Movement Scale) is standard practice. See our explainer on tardive dyskinesia.

Neuroleptic malignant syndrome

Rare but serious. Symptoms include high fever, severe muscle rigidity, autonomic instability (blood pressure swings, sweating), and altered consciousness. It is a medical emergency.

Other effects worth knowing

• Sexual side effects — generally less than with prolactin-raising antipsychotics like risperidone, but possible
• Orthostatic hypotension — dizziness on standing, especially during titration
• Mild prolactin changes — usually less than other antipsychotics; aripiprazole can sometimes lower prolactin in people whose levels were elevated by another medication

Boxed warnings

Like all antipsychotics, aripiprazole has FDA boxed warnings for:

• Increased mortality in elderly patients with dementia-related psychosis
• Increased risk of suicidal thoughts and behaviour in children, adolescents, and young adults treated for depression

What patients commonly say

• "It worked, but I couldn't stop pacing for the first month."
• "I switched from olanzapine and lost weight without trying — but I started having to sleep with melatonin."
• "I gambled away three months of savings before I realised the medication might be doing something to me."
• "For the first time in years, I felt like myself but without the voices."

Questions for your prescriber

• What should I do if I feel restless or agitated?
• How will we monitor for involuntary movements over time?
• Are there any new urges or behaviours you'd want me to report?
• How often will my metabolic labs be checked?
• If I want to discontinue, how would we taper?

Putting it together

Aripiprazole is a useful and often well-tolerated antipsychotic — particularly for patients who can't afford to gain weight or who felt overly sedated on prior medications. Its side effects are real but are often manageable with dose adjustments, timing changes, or short-term add-on medications. The keys are honesty with your prescriber about how you feel, regular monitoring, and watching for the rarer but more serious effects.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.